Mounjaro (tirzepatide) is not an SGLT2 inhibitor. It belongs to a distinct class of diabetes medications known as dual GIP and GLP-1 receptor agonists. Whilst both Mounjaro and SGLT2 inhibitors are used to manage type 2 diabetes, they work through entirely different mechanisms and have unique clinical profiles. Understanding these differences is essential for patients and healthcare professionals when selecting appropriate treatment. This article clarifies the pharmacological distinctions between Mounjaro and SGLT2 inhibitors, explores their respective mechanisms of action, and examines when each therapy may be most suitable for individual patients with type 2 diabetes.

Understanding Mounjaro: Mechanism of Action and Drug Class

Mounjaro is not an SGLT2 inhibitor. It belongs to an entirely different class of diabetes medications known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. The active ingredient, tirzepatide, represents a novel therapeutic approach that simultaneously activates two incretin hormone receptors.

Incretin hormones are naturally produced in the gut following food intake and play crucial roles in glucose regulation. Tirzepatide works by mimicking these hormones, binding to both GIP and GLP-1 receptors throughout the body. This dual action stimulates insulin secretion from pancreatic beta cells when blood glucose levels are elevated, whilst simultaneously suppressing glucagon release from alpha cells. Importantly, this glucose-dependent mechanism means insulin secretion only occurs when needed, reducing the risk of hypoglycaemia.

Beyond glucose control, Mounjaro affects multiple physiological pathways. It slows gastric emptying, which moderates the rate at which nutrients enter the bloodstream after meals. This gastric-slowing effect may reduce exposure to oral contraceptives during treatment initiation and dose increases, so additional contraceptive methods are recommended for 4 weeks after starting treatment and after each dose increase. The medication also acts on appetite centres in the brain, promoting satiety and reducing food intake. These combined effects contribute to significant weight loss alongside glycaemic improvements.

Mounjaro is administered as a once-weekly subcutaneous injection. Treatment starts with 2.5 mg weekly for 4 weeks, then increases to 5 mg. Further dose increases can be made in 2.5 mg increments to 5, 10 or 15 mg based on clinical response and tolerability. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved it for adults with type 2 diabetes mellitus as an adjunct to diet and exercise, either as monotherapy when metformin is inappropriate or in combination with other diabetes medications.

What Are SGLT2 Inhibitors and How Do They Work?

Sodium-glucose co-transporter 2 (SGLT2) inhibitors represent a distinct class of oral antidiabetic medications that work through an entirely different mechanism from Mounjaro. These drugs target the kidneys rather than the incretin system, offering a unique insulin-independent approach to glucose management.

The kidneys normally filter glucose from the blood, then reabsorb most of it back into circulation through specialised transport proteins. SGLT2 proteins, located in the proximal tubule of the nephron, are responsible for reabsorbing approximately 90% of filtered glucose. SGLT2 inhibitors block these transporters, preventing glucose reabsorption and causing excess glucose to be excreted in the urine. This mechanism reduces blood glucose levels without directly affecting insulin secretion or sensitivity.

Commonly prescribed SGLT2 inhibitors in the UK include dapagliflozin (Forxiga), empagliflozin (Jardiance), and canagliflozin (Invokana). These medications are typically taken once daily as oral tablets, offering convenience compared to injectable therapies.

Beyond glycaemic control, SGLT2 inhibitors provide additional cardiovascular and renal benefits. Clinical trials have demonstrated reduced risks of heart failure hospitalisation across the class, with some agents showing cardiovascular death reduction in specific populations. Many SGLT2 inhibitors have also shown benefits in slowing progression of chronic kidney disease. These protective effects have led to NICE recommending SGLT2 inhibitors for patients with type 2 diabetes who have established cardiovascular disease, heart failure or chronic kidney disease.

Common adverse effects include increased urination (due to glucose excretion), genital and urinary tract infections (as glucose in urine creates a favourable environment for microorganisms), and volume depletion in susceptible individuals. Rare but serious complications include diabetic ketoacidosis (even with near-normal glucose levels) and Fournier's gangrene.

Importantly, SGLT2 inhibitors should be temporarily stopped during periods of acute illness, dehydration, or fasting, and for 3 days before major surgery to reduce the risk of diabetic ketoacidosis. Renal function should be checked before starting treatment, with specific eGFR thresholds for initiation varying by agent and indication. Patients should maintain adequate hydration and seek medical attention if they develop symptoms of infection or ketoacidosis.

Key Differences Between Mounjaro and SGLT2 Inhibitors

Mounjaro and SGLT2 inhibitors differ fundamentally in their pharmacological mechanisms, administration routes, and clinical effects, despite both being used to manage type 2 diabetes.

Mechanism and site of action: Mounjaro works systemically through incretin receptor activation, affecting the pancreas, gastrointestinal tract, and central nervous system. It enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. In contrast, SGLT2 inhibitors act primarily on the kidneys, blocking glucose reabsorption and promoting urinary glucose excretion through an insulin-independent pathway.

Administration and dosing: Mounjaro requires once-weekly subcutaneous injection, with doses escalated gradually from 2.5 mg to a maintenance dose (typically 5–15 mg) to minimise gastrointestinal side effects. SGLT2 inhibitors are oral medications taken once daily, offering greater convenience for patients who prefer not to inject.

Weight effects: Both medication classes promote weight loss, but through different mechanisms. Mounjaro typically produces more substantial weight reduction (often 5–10 kg or more) due to its appetite-suppressing effects and delayed gastric emptying. SGLT2 inhibitors cause modest weight loss (usually 2–3 kg) primarily through caloric loss via urinary glucose excretion.

Adverse effect profiles: Mounjaro commonly causes gastrointestinal symptoms including nausea, vomiting, and diarrhoea, particularly during dose escalation. Acute pancreatitis has been reported with incretin-based therapies; patients should stop treatment and seek medical attention if severe, persistent abdominal pain occurs. Animal studies have shown thyroid C-cell tumours with tirzepatide, though the relevance to humans is uncertain. SGLT2 inhibitors are associated with genitourinary infections, volume depletion, and rare cases of euglycaemic ketoacidosis.

Cardiovascular and renal outcomes: SGLT2 inhibitors have robust evidence for cardiovascular and renal protection, with demonstrated reductions in heart failure hospitalisation and kidney disease progression. Whilst Mounjaro shows promising cardiovascular benefits in clinical trials, the evidence base is still developing. These fundamental differences inform clinical decision-making when selecting appropriate therapy for individual patients.

Can Mounjaro and SGLT2 Inhibitors Be Used Together?

Yes, Mounjaro and SGLT2 inhibitors can be prescribed together, and this combination may offer complementary benefits for selected patients with type 2 diabetes. Because these medications work through entirely different mechanisms—incretin activation versus renal glucose excretion—they do not interfere with each other's pharmacological actions.

Combination therapy may be considered when monotherapy or dual therapy fails to achieve adequate glycaemic control. The complementary mechanisms can provide additive glucose-lowering effects: Mounjaro enhances insulin secretion and reduces appetite, whilst the SGLT2 inhibitor promotes glucose excretion and offers cardiovascular protection. This approach aligns with NICE guidance on intensifying diabetes treatment when HbA1c targets are not met with existing therapies.

Patients receiving both medications may benefit from enhanced weight loss and potentially greater cardiovascular risk reduction. The SGLT2 inhibitor's proven benefits in heart failure and chronic kidney disease complement Mounjaro's metabolic effects, making this combination particularly attractive for patients with multiple comorbidities.

However, healthcare professionals must carefully consider the cumulative adverse effect burden. Patients may experience gastrointestinal symptoms from Mounjaro alongside genitourinary infections from the SGLT2 inhibitor. Volume depletion risk may be heightened, particularly in older adults or those taking diuretics. Close monitoring during treatment initiation is essential.

Hypoglycaemia risk remains low with this combination when used without insulin or sulphonylureas, as both drug classes have glucose-dependent or insulin-independent mechanisms. Nevertheless, if patients are taking other glucose-lowering medications, dose adjustments may be necessary.

Regular monitoring should include HbA1c, weight, renal function, blood pressure, and review of adverse effects. Remember that SGLT2 inhibitors should be temporarily stopped during acute illness, dehydration, or before major surgery to reduce diabetic ketoacidosis risk.

The decision to combine these therapies should be individualised, considering the patient's glycaemic control, weight, cardiovascular risk profile, renal function, and tolerance of potential side effects. Regular review of treatment efficacy and safety is essential, with adjustments made according to clinical response and patient preference.

Choosing the Right Diabetes Medication: Clinical Considerations

Selecting between Mounjaro, SGLT2 inhibitors, or other diabetes medications requires a comprehensive, patient-centred approach that considers multiple clinical and personal factors. NICE guidance emphasises individualised treatment decisions based on efficacy, safety, tolerability, and patient preferences.

Glycaemic efficacy and weight: When substantial HbA1c reduction and weight loss are priorities, Mounjaro often demonstrates superior efficacy compared to many other agents, including SGLT2 inhibitors. Clinical trials show tirzepatide can reduce HbA1c by 1.5–2.5% (16–27 mmol/mol) with significant weight loss. SGLT2 inhibitors typically reduce HbA1c by 0.5–1.0% (5–11 mmol/mol) with modest weight reduction. For patients with obesity and inadequate glycaemic control, Mounjaro may be preferred, whilst SGLT2 inhibitors suit those seeking moderate glucose lowering with cardiovascular protection.

Cardiovascular and renal considerations: For patients with established cardiovascular disease, heart failure, or chronic kidney disease, NICE recommends offering SGLT2 inhibitors (with or without metformin as appropriate) due to robust evidence of organ protection. SGLT2 inhibitors should also be considered for those at high cardiovascular risk. Mounjaro shows cardiovascular benefits in trials, but the evidence base is less extensive.

Patient factors and preferences: Administration route matters significantly. Patients uncomfortable with injections may prefer oral SGLT2 inhibitors, whilst those seeking maximum efficacy may accept weekly injections. Gastrointestinal tolerance is crucial for Mounjaro, as nausea can be limiting. Patients prone to urinary infections may find SGLT2 inhibitors problematic.

Cautions and monitoring: Animal studies with tirzepatide have shown thyroid C-cell tumours, though the relevance to humans is uncertain. Patients should report symptoms such as a lump in the neck, difficulty swallowing, or persistent hoarseness. For SGLT2 inhibitors, renal function should be checked before initiation and periodically during treatment, with specific eGFR thresholds guiding use.

Pregnancy and breastfeeding: Neither Mounjaro nor SGLT2 inhibitors are recommended during pregnancy or breastfeeding. SGLT2 inhibitors are contraindicated in later pregnancy. Women of childbearing potential should discuss preconception planning and may need to switch to insulin-based regimens when planning pregnancy.

Cost and accessibility: NHS prescribing policies and local formularies may influence availability. Patients should discuss treatment options with their GP or diabetes specialist, considering their individual circumstances, comorbidities, and treatment goals. Regular monitoring and treatment review ensure optimal diabetes management whilst minimising adverse effects.

Patients are encouraged to report any suspected side effects to the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

Frequently Asked Questions